|Articles|November 15, 2002
- BioPharm International-11-01-2002
- Volume 15
- Issue 11
Guest Editorial: Back to the Beginning
Author(s)Stefan Schuber
by Stefan Schuber, U.S. Pharmacopeia
Advertisement
Articles in this issue
almost 23 years ago
Inside Washington: Major Changes Ahead for FDAalmost 23 years ago
Bioinformatics Databases ? Questions of Copyrightalmost 23 years ago
European Editor's Report ? An Industry Comes of Agealmost 23 years ago
You Have Failed . . . A Case Study in Warning Letter Remediationalmost 23 years ago
Survival Guide to FDA Inspections: Part 3, Responding to ObservationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Challenges, Innovations, and Future Outlook of Biologics Formulations
2
A-TEEM: A Novel, Powerful Tool for Evaluating and Monitoring Cell Culture Media
3
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
4
Global Study Confirms Survival Advantage of Mogamulizumab in Advanced Mycosis Fungoides and Sézary Syndrome
5